Dr John Campbell
@campbellteaching·3.3M subscribers·3.1K videos
Compared vaccine adverse effects
Posted
April 16, 2021
Views
224,552
Likes
6,654
Comments
2,040
Engagement
3.87%
April 16, 2021
224,552
6,654
2,040
3.87%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
22:44Now PlayingIndia
Cases, + 216,850
Deaths, + 1,183 = 174,308
Vaccinations, 117,223,509
Infection drivers
Workplaces
Markets and malls have reopened
Transport operating at full capacity
Big weddings
Festivals
Election rallies
Probable new variants
Israel
Population 9.3 million
US and UK vaccination rates
UK, 48% of overall population
I guess the difference won't bother most news consumers much but I'd like to think your viewers might be more discerning, (Tony)
Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID -19 cases and a comparison with 489,871 people receiving a COVID -19 mRNA vaccine
Can help contextualize the risks and benefits of vaccination in this regard
Using an electronic health records network
Absolute incidence of cerebral venous thrombosis (CVT) in the two weeks following:
(Incidence of portal vein thrombosis, PVT also assessed)
COVID-19 diagnosis (N=513,284)
Influenza (N=172,742)
Receipt of the BNT162b2 (Pfizer) or mRNA-1273 (Moderna) COVID-19 vaccines (N=489,871)
The incidence of CVT after COVID-19 diagnosis
CVT = 39.0 per million people
The incidence of CVT after influenza diagnosis
CVT = Zero per million people
Incidence of CVT after receiving BNT162b2 or mRNA-1273 vaccine
CVT = 4.1 per million people
The incidence of PVT after COVID-19 diagnosis
PVT = 436
The incidence of PVT after influenza diagnosis
PVT = 98
Incidence of PVT after receiving BNT162b2 or mRNA-1273 vaccine
PVT = 44 per million
CVT incidence observed across the entire health records network
0.41 per million people over any 2-week period
Laboratory test results, available in a subset of the COVID-19 patients, suggestive of:
Raised D-dimer, lowered fibrinogen, and an increased rate of thrombocytopenia in the CVT and PVT groups
CVT Mortality = 20% in 2 weeks after CoViD
PVT mortality = 18.8% in 2 weeks after CoViD
Latest estimate from the European Medicines Agency
Incidence associated with ChAdOx1 nCoV-19 vaccine
CVT = 5.0 per million people
Splanchnic thrombosis by the EMA following vaccination with ChAdOx1
(portal, splenic, mesenteric)
53 cases out of 34 million people
1.6 per million people
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
